2025
Architects of immunity: How dendritic cells shape CD8+ T cell fate in cancer. Bhandarkar V, Dinter T, Spranger S. Sci Immunol. 2025 Jan 17;10(103):eadf4726. doi: https://doi.org/10.1126/sciimmunol.adf4726. Epub 2025 Jan 17. PMID: 39823318 Review.
Lung cancer–intrinsic SOX2 expression mediates resistance to checkpoint blockade therapy by inducing Treg cell–dependent CD8+ T-cell exclusion. Torres-Mejia E, Nguyen K, Weng S, Duong E, Yim L, Spranger S. Cancer Immuno Res 2025 online first https://doi.org/10.1158/2326-6066.CIR-24-0184
Cancer immune evasion, immunoediting and intratumour heterogeneity. Roerden M, Spranger S. Nat Rev Immunol. 2025 Jan 2. doi: https://doi.org/10.1038/s41577-024-01111-8. Online ahead of print. PMID: 39748116 Review.
2024
Neoantigen architectures define immunogenicity and drive immune evasion of tumors with heterogenous neoantigen expression. Roerden M, Castro AB, Cui Y, Harake N, Kim B, Dye J, Maiorino L, White FM, Irvine DJ, Litchfield K, Spranger S. J Immunother Cancer. 2024 Nov 9;12(11):e010249. doi: 10.1136/jitc-2024-010249. PMID: 39521615
Validation and quantification of peptide antigens presented on MHCs using SureQuant. Leddy O, Cui Y, Ahn R, Stopfer L, Choe E, Kim DH, Roerden M, Spranger S, Bryson BD, White FM. Nat Protoc. 2024 Oct 22. doi: https://doi.org/10.1038/s41596-024-01076-x. Online ahead of print. PMID: 39438697
Expansion of tumor-reactive CD8+ T cell clonotypes occurs in the spleen in response to immune checkpoint blockade. Morgan DM, Horton BL, Bhandarkar V, Van R, Dinter T, Zagorulya M, Love JC, Spranger S. Sci Immunol. 2024 Sep 13;9(99):eadi3487. doi: https://doi.org/10.1126/sciimmunol.adi3487. Epub 2024 Sep 13. PMID: 39270006
2023
Overcoming Lung Cancer Immunotherapy Resistance by Combining Non-Toxic Variants Of IL-12 and IL-2. Horton BL, D’Souza AD, Zagorulya M, McCreery CV, Abhiraman GC, Picton L, Sheen A, Agarwal Y, Momin N, Wittrup KD, White FM, Garcia KC, Spranger S JCI Insight. 2023 Sep 5;. doi: https://doi.org/10.1172/jci.insight.172728. [Epub ahead of print] PubMed PMID: 37669107.
Decoupled neoantigen cross-presentation by dendritic cells limits anti-tumor immunity against tumors with heterogeneous neoantigen expression. Nguyen KB, Roerden M, Copeland CJ, Backlund CM, Klop-Packel NG, Remba T, Kim B, Singh NK, Birnbaum ME, Irvine DJ, Spranger S. Elife. 2023 Aug 7;12:e85263. doi: https://doi.org/10.7554/eLife.85263. PMID: 37548358
Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodies. Lax BM, Palmeri JR, Lutz EA, Sheen A, Stinson JA, Duhamel L, Santollani L, Kennedy A, Rothschilds AM, Spranger S, Sansom DM, Wittrup KD. Proc Natl Acad Sci U S A. 2023 Aug;120(31):e2300895120. doi: https://doi.org/10.1073/pnas.2300895120. Epub 2023 Jul 24. PubMed PMID: 37487077
A prime editor mouse to model a broad spectrum of somatic mutations in vivo. Ely ZA, Mathey-Andrews N, Naranjo S, Gould SI, Mercer KL, Newby GA, Cabana CM, Rideout WM 3rd, Jaramillo GC, Khirallah JM, Holland K, Randolph PB, Freed-Pastor WA, Davis JR, Kulstad Z, Westcott PMK, Lin L, Anzalone AV, Horton BL, Pattada NB, Shanahan SL, Ye Z, Spranger S, Xu Q, Sánchez-Rivera FJ, Liu DR, Jacks T. Nat Biotechnol. 2023 May 11. doi: https://doi.org/10.1038/s41587-023-01783-y. [Epub ahead of print] PubMed PMID: 37169967
Engineering kinetics of TLR7/8 agonist release from bottlebrush prodrugs enables tumor-focused immune stimulation. Bhagchandani SH, Vohidov F, Milling LE, Tong EY, Brown CM, Ramseier ML, Liu B, Fessenden TB, Nguyen HV, Kiel GR, Won L, Langer RS, Spranger S, Shalek AK, Irvine DJ, Johnson JA. Sci Adv. 2023 Apr 21;9(16):eadg2239. doi: https://doi.org/10.1126/sciadv.adg2239. Epub 2023 Apr 19. PubMed PMID: 37075115
MHC-dressing on dendritic cells: Boosting anti-tumor immunity via unconventional tumor antigen presentation. Chatterjee F, Spranger S. Semin Immunol. 2023 Mar;66:101710. doi: https://doi.org/10.1016/j.smim.2023.101710. Epub 2023 Jan 12. PMID: 36640616 Review.
Tissue-specific abundance of interferon-gamma drives regulatory T cells to restrain DC1-mediated priming of cytotoxic T cells against lung cancer. Zagorulya M, Yim L, Morgan DM, Edwards A, Torres-Mejia E, Momin N, McCreery CV, Zamora IL, Horton BL, Fox JG, Wittrup KD, Love JC, Spranger S. Immunity. 2023 Feb 14;56(2):386-405.e10. doi: https://doi.org/10.1016/j.immuni.2023.01.010. Epub 2023 Feb 2. PMID: 36736322
2022
Mesenchymal and adrenergic cell lineage states in neuroblastoma possess distinct immunogenic phenotypes. Sengupta S, Das S, Crespo AC, Cornel AM, Patel AG, Mahadevan NR, Campisi M, Ali AK, Sharma B, Rowe JH, Huang H, Debruyne DN, Cerda ED, Krajewska M, Dries R, Chen M, Zhang S, Soriano L, Cohen MA, Versteeg R, Jaenisch R, Spranger S, Romee R, Miller BC, Barbie DA, Nierkens S, Dyer MA, Lieberman J, George RE. Nat Cancer. 2022 Oct;3(10):1228-1246. doi: https://doi.org/10.1038/s43018-022-00427-5. Epub 2022 Sep 22. PMID: 36138189
Alum-anchored intratumoral retention improves the tolerability and antitumor efficacy of type I interferon therapies. Lutz EA, Agarwal Y, Momin N, Cowles SC, Palmeri JR, Duong E, Hornet V, Sheen A, Lax BM, Rothschilds AM, Irvine DJ, Spranger S, Wittrup KD. Proc Natl Acad Sci U S A. 2022 Sep 6;119(36):e2205983119. doi: https://doi.org/10.1073/pnas.2205983119. Epub 2022 Aug 29.
Deciphering the immunopeptidome in vivo reveals new tumour antigens. Jaeger AM, Stopfer LE, Ahn R, Sanders EA, Sandel DA, Freed-Pastor WA, Rideout WM 3rd, Naranjo S, Fessenden T, Nguyen KB, Winter PS, Kohn RE, Westcott PMK, Schenkel JM, Shanahan SL, Shalek AK, Spranger S, White FM, Jacks T.Nature. 2022 Jul;607(7917):149-155. doi: https://doi.org/10.1038/s41586-022-04839-2. Epub 2022 Jun 15.
Dendritic cell-mediated cross-presentation of tumor-derived peptides is biased against plasma membrane proteins. Fessenden TB, Stopfer LE, Chatterjee F, Zulueta J, Mesfin JM, Cordero Dumit T, Reijers ILM, Hoefsmit EP, Blank CU, White F, and Spranger S (J Immunother Cancer. 2022 Jul;10(7):e004159. doi: https://doi.org/10.1136/jitc-2021-004159)
Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ T cell immunity. Duong E, Fessenden TB, Lutz E, Dinter T, Yim L, Blatt S, Bhutkar A, Wittrup KD, Spranger S. Immunity. 2022 Feb 8;55(2):308-323.e9. doi: https://doi.org/10.1016/j.immuni.2021.10.020. Epub 2021 Nov 19. PMID: 34800368
2021
Lack of CD8+ T cell effector differentiation during priming mediates checkpoint blockade resistance in non-small cell lung cancer. Horton BL, Morgan DM, Momin N, Zagorulya M, Torres-Mejia E, Bhandarkar V, Wittrup KD, Love JC, Spranger S. Sci Immunol. 2021 Oct 29;6(64):eabi8800. doi: https://doi.org/10.1126/sciimmunol.abi8800. Epub 2021 Oct 29. PMID: 34714687
Reprogramming NK cells and macrophages via combined antibody and cytokine therapy primes tumors for elimination by checkpoint blockade. Wang C, Cui A, Bukenya M, Aung A, Pradhan D, Whittaker CA, Agarwal Y, Thomas A, Liang S, Amlashi P, Suh H, Spranger S, Hacohen N, Irvine DJ.Cell Rep. 2021 Nov 23;37(8):110021. doi: https://doi.org/10.1016/j.celrep.2021.110021. PMID: 34818534
2020
Increased demand for NAD+ relative to ATP drives aerobic glycolysis. Luengo A, Li Z, Gui DY, Sullivan LB, Zagorulya M, Do BT, Ferreira R, Naamati A, Ali A, Lewis CA, Thomas CJ, Spranger S, Matheson NJ, Vander Heiden MG. Mol Cell. 2020 Dec 22:S1097-2765(20)30904-7. doi: https://doi.org/10.1016/j.molcel.2020.12.012.
Direct and Indirect Regulators of Epithelial-Mesenchymal Transition (EMT)-mediated Immunosuppression in Breast Carcinomas. Dongre A, Rashidian M, Eaton EN, Reinhardt F, Thiru P, Zagorulya M, Nepal S, Banaz T, Martner A, Spranger S, Weinberg RA. Cancer Discov. 2020 Dec 16:CD-20-0603. doi: https://doi.org/10.1158/2159-8290.CD-20-0603.
Formation of Human Neuroblastoma in Mouse-Human Neural Crest Chimeras. Cohen MA, Zhang S, Sengupta S, Ma H, Bell GW, Horton B, Sharma B, George RE, Spranger S, Jaenisch R. Cell Stem Cell. 2020 Apr 2;26(4):579-592.e6. doi: https://doi.org/10.1016/j.stem.2020.02.001.
2019
Anchoring of intratumorally administered cytokines to collagen safely potentiates systemic cancer immunotherapy. Momin N, Mehta NK, Bennett NR, Ma L, Palmeri JR, Chinn MM, Lutz EA, Kang B, Irvine DJ, Spranger S, Wittrup KD. Sci Transl Med. 2019 Jun 26;11(498):eaaw2614. doi: https://doi.org/10.1126/scitranslmed.aaw2614. PMID: 31243150
WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers. Luke JJ, Bao R, Sweis RF, Spranger S, Gajewski TF. Clin Cancer Res. 2019 Jan 11. doi: https://doi.org/10.1158/1078-0432.CCR-18-1942.CCR-18-1942.
2017
Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. Spranger S, Dai D, Horton B, Gajewski TF. Cancer Cell. 2017 May 8;31(5):711-723.e4. doi: https://doi.org/10.1016/j.ccell.2017.04.003.
2016
Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma. Spranger S, Luke JJ, Bao R, Zha Y, Hernandez KM, Li Y, Gajewski AP, Andrade J, Gajewski TF. Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):E7759-E7768. doi: https://doi.org/10.1073/pnas.1609376113
2015
Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Spranger S, Bao R, and Gajewski TF, Nature. 2015 Jul 9;523(7559):231-5. doi: https://doi.org/10.1038/nature14404.
2014
STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors. Woo SR, Fuertes MB, Corrales L, Spranger S, Furdyna MJ, Leung M, Duggan R, Wang Y, Barber GN, Fitzgerald KA, Alegre M, Gajewski TF, Immunity. 2014 Nov 20;41(5):830-42. doi: https://doi.org/10.1016/j.immuni.2014.10.017.
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment. Spranger S, Koblish H, Horton B, Scherle P, Newton R, Gajewski TF, J Immunother Cancer. 2014 Feb 18;2:3. doi: https://doi.org/10.1186/2051-1426-2-3.
2013
Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, Gajewski TF, Sci Transl Med. 2013 Aug 28;5(200):200ra116. doi: https://doi.org/10.1126/scitranslmed.3006504.